Detalhe da pesquisa
1.
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.
Alzheimers Dement (N Y)
; 8(1): e12273, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229025